Product Description
The U.S. and European insulin markets include long-acting insulin, ultra-long-acting insulin, rapid-acting insulin, premixed insulin, and human insulin. Within both the U.S. and the European markets the largest segment was the long-acting insulin market, which accounted for over 37% of the total market value. The long-acting insulin market has experienced increased competition, due to the expiration of product patents and the rise of biosimilar products.
Over the forecast period, the value for both the U.S. and the European insulin markets is expected to increase over the forecast period. The U.S. market is expected to reach approximately $8 billion and the European market is expected to reach approximately €3 billion by 2025.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Market Drivers & Limiters
- Market Forecasts Until 2025, and Historical Data to 2015
- Company Profiles and Product Portfolios
- Leading Competitors
U.S. INSULIN MARKET INSIGHTS
The largest segment was the long-acting insulin market, which accounted for over 37% of the total market value. The long-acting insulin market has experienced increased competition, due to the expiration of product patents and the rise of biosimilar products. The second-largest segment was the rapid-acting insulin market. Increased adoption of insulin pump therapy will contribute to the growth of this market, as rapid-acting insulin is used for continuous subcutaneous insulin infusion (CSII). The third-largest segment was the ultra-long-acting insulin market.
EUROPE’S INSULIN MARKET INSIGHTS
The largest segment was the long-acting insulin market. The long-acting insulin market has experienced increased competition, due to the expiration of product patents and the rise of biosimilar products. The second-largest segment was the rapid-acting insulin market. Increased adoption of insulin pump therapy will contribute to the growth of this market, as rapid-acting insulin is used for continuous subcutaneous insulin infusion (CSII). The third-largest segment was the ultra-long-acting insulin market. The ultra-long-acting insulin market has exhibited significant growth since the first product was launched in 2014.
U.S. AND EUROPEAN INSULIN MARKET SHARE INSIGHTS
Novo Nordisk, Sanofi, and Eli Lilly controlled both the U.S. and European insulin markets.
Novo Nordisk held the leading position in the ultra-long-acting insulin and rapid-acting insulin markets and the second-leading position in the long-acting insulin, premixed insulin, and human insulin markets.
REPORT REGIONAL COVERAGE
Throughout this research series, iData has covered several countries in great detail. The covered countries are:
- North America (United States)
- Europe (Germany, France, United Kingdom, Italy, Spain, Benelux (Belgium, Netherlands, and Luxembourg), Scandinavia (Denmark, Finland, Norway, and Sweden), Austria, Switzerland, and Portugal)
